Mueller Industries (MLI) reported a year-over-year increase in fiscal Q3 adjusted diluted earnings and net sales late Monday.
Shares jumped 16%, with intraday trading volume at over 1.17 million compared with a daily average of about 777,000.
Indaptus Therapeutics (INDP) disclosed a clinical supply agreement late Tuesday with BeiGene (BGNE).
Indaptus plans to advance human clinical evaluation of a combination of BeiGene's anti-PD-1 antibody, tislelizumab, with its Decoy20, a novel treatment designed to induce a broad immune response to fight cancer. As part of the agreement, BeiGene will also provide technical expertise to accelerate the first clinical trial combining the two investigational drugs.
Shares of Indaptus advanced 16% as intraday trading volume climbed to over 4.03 million from a daily average of about 17,000.
General Motors (GM) reported a year-over-year jump in Q3 adjusted earnings and revenue, beating market expectations.
Shares jumped 9.2% as intraday trading volume surged to more than 28.1 million from a daily average of about 13.6 million.
Price: 83.72, Change: +11.64, Percent Change: +16.14
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。